Dr. Reddy's Laboratories Ltd. closed 13.86% short of its 52-week high of 1,420.20 rupees, which the company reached on August 21st.

Dr. Reddy's Laboratories Ltd. closed 14.39% short of its 52-week high of 1,420.20 rupees, which the company achieved on ...

Indian shares opened on a sluggish note Monday amid fresh tariff and inflation jitters after a measure of U.S. inflation expectations ...

Dr. Reddy's Laboratories DRREDDY RDY has delivered a set of financial results. For the third quarter (Q3FY25) and the nine months (9MFY25) ending December 31, 2024, the company showcased robust ...

Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...

Analysis of Growth Trends and Shares, Globally and at the Country-Level, by End Use Application and Sales Channel Omeprazole Market Omeprazole Market Dublin, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

HYDERABAD: Dr Reddy’s Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma biggie Dr Reddy’s ...

Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a ...

Dr. Reddy's Laboratories is among India’s leading pharmaceutical companies. The company is primarily known for manufacturing active pharmaceutical ingredients (APIs). Dr. Reddy's Laboratories ...